Switching from Apixaban to Enoxaparin
Apixaban can be discontinued and enoxaparin can be started at the time the next apixaban dose would be due. [1][2]
Bridging with heparin or LMWH during the brief interval after stopping apixaban for procedures is generally not required. [1][3]
Medication Selection Algorithm
Switching from apixaban to an alternative anticoagulant other than warfarin is performed by discontinuing apixaban and starting the new anticoagulant at the usual time of the next apixaban dose. [1]
Common clinical contexts for a transition strategy include:
- Acute change in anticoagulant plan in the acute care setting. [3]
- Periprocedural anticoagulation management. [1][3]
Practical Switching Timing
For a switch from apixaban to LMWH (including enoxaparin), apixaban should be discontinued and the first LMWH dose should be given at the time the next apixaban dose is due. [2]
Overlap of apixaban with LMWH is not indicated by standard labeled/transition guidance. [1][2]
Initiation Thresholds and Indications
The timing strategy above applies to routine transitions between anticoagulants other than warfarin. [1][2]
Periprocedural management should follow apixaban interruption guidance based on procedure bleeding risk. [1][3]
Bridging anticoagulation during the 24 to 48 hours after stopping apixaban and prior to intervention is not generally required. [1]
Renal Function and Dosing Individualization
Enoxaparin initiation requires patient-specific dosing adjustment based on indication and renal function. [2]
No single enoxaparin dose recommendation can be provided without the target anticoagulation intensity and the patient’s renal function. [2]
Common Pitfalls to Avoid
Bridging anticoagulation with heparin or LMWH during short DOAC interruption periods is generally avoided because the time without anticoagulation is brief. [1]
Starting enoxaparin before the next scheduled apixaban dose can create unnecessary overlap in anticoagulant effect. [1][2]
Target Outcomes of the Transition
The transition goal is maintenance of anticoagulation coverage with minimized time without anticoagulation. [1][2]
Periprocedural management aims to limit residual anticoagulant effect at the time of intervention while avoiding prolonged anticoagulation interruption. [1]
Post-Transition Monitoring Considerations
After restarting an anticoagulant post-procedure, resumption should occur once adequate hemostasis is established. [1]
Anticoagulant changes should be coordinated with the intended indication (stroke prevention vs VTE treatment vs other) because therapeutic intensity determines enoxaparin dosing strategy. [2]